Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Core Viewpoint - Iovance Biotherapeutics, Inc. faces a class action lawsuit following a significant decline in its financial performance and revenue guidance, leading to a sharp drop in its stock price [1][2][3]. Financial Performance - For Q1 2025, Iovance reported total product revenue of $49.3 million, down from $73.7 million in the previous quarter, indicating a decline of approximately 33% [2]. - The company revised its full fiscal year 2025 revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [2]. Lawsuit Details - The class action lawsuit alleges that Iovance made materially false and misleading statements regarding its business operations and prospects during the class period [3]. - Specific allegations include delays in new Authorized Treatment Centers (ATCs) beginning patient treatments, inefficiencies in patient identification and selection, and resulting higher costs and lower revenues due to ATCs not keeping pace with manufactured products [3]. Legal Action - Investors who purchased Iovance securities during the class period have until July 14, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].